Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing

• Egile Nagusiak: Zhiru Wang (Egilea), Wenting Kang (Egilea), Ouwen Li (Egilea), Fengyu Qi (Egilea), Junwei Wang (Egilea), Yinghua You (Egilea), Pengxing He (Egilea), Zhenhe Suo (Egilea), Yichao Zheng (Egilea), Hong-Min Liu (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2021-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Targeting immune checkpoints such as programmed cell death protein 1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved for treating melanoma, gastric cancer (GC) and bladder cancer with clinical benefit. Nevertheless, many patients failed to respond to anti-PD-1/PD-L1 treatment, so it...